evipedia.ai
← Back

Laser Resurfacing for Skin Rejuvenation

Evidence Review created on 09/11/2026 using AI4L / Opus 5

Also known as: Laser Skin Resurfacing, Ablative Laser Resurfacing, Fractional Laser Resurfacing, Fractional Photothermolysis, Laserabrasion, Laser Peel

Motivation

Laser resurfacing uses a focused beam of light to remove or heat a controlled fraction of the skin’s surface and the layer beneath it, so that the body rebuilds what was injured. Devices vary widely: some strip the outer layer across the whole treated area; others injure only microscopic columns of tissue and leave untouched skin between them to speed repair. What draws attention is that the change is structural: the skin is rebuilt rather than coated.

Surgeons began treating facial skin with carbon dioxide lasers in the 1990s, and the column-based approach that followed a decade later cut recovery time sharply and made the procedure one of the most widely performed energy-based treatments in the world. Interest has since broadened beyond appearance, because the same controlled wounding appears to clear sun-damaged and aged cells from the skin, raising the question of whether it also lowers later skin cancer risk.

This review examines what the evidence shows about laser resurfacing as a skin-rejuvenation intervention: the size and durability of the changes reported, how the tissue-removing and tissue-heating approaches compare, the pigment, scarring and infection problems that can follow, and how the preventive claims stand beside the cosmetic ones.

Benefits - Risks - Protocol - Conclusion

This section lists high-level, non-systematic sources that give a broad orientation to laser resurfacing from clinical, expert and preventive perspectives.

Content from Rhonda Patrick (foundmyfitness.com), Chris Kresser (chriskresser.com) and Lifespan.io could not be found: an on-site search of foundmyfitness.com for “laser resurfacing” returned no results, Chris Kresser’s skin material is confined to nutrition, gut health and skin microbiota, and Lifespan.io covers skin ageing through senescent-cell biology rather than energy-based procedures. Five qualifying sources were identified, so the list is not padded.

Grokipedia

Laser Skin Resurfacing

A dedicated encyclopedia entry covering device classes, tissue-removing versus tissue-heating mechanisms, indications, complication profiles and aftercare, useful as a neutral orientation before reading the primary clinical literature.

Examine

No Examine article on laser resurfacing exists. A direct site search returned only Red Light Therapy and Low-Level Laser Therapy pages plus unrelated study summaries. Examine covers supplements and nutrients, not clinician-performed procedures.

ConsumerLab

No ConsumerLab article on laser resurfacing exists. A direct site search returned only a collagen supplement review, a red-light question-and-answer page and a laser hair-cap update. ConsumerLab tests supplements, not procedures.

Systematic Reviews

This section lists the systematic reviews and meta-analyses that best define what laser resurfacing achieves and what it costs in adverse events.

Two structural biases run through this literature and are worth naming before reading it. First, most primary trials behind these syntheses are funded or equipped by laser manufacturers, and the consensus documents cited throughout this review are written by professional bodies — among them the American Society for Laser Medicine and Surgery and the American Society for Dermatologic Surgery — whose members’ practices derive direct revenue from performing resurfacing; the same applies symmetrically to the plastic-surgery and dermatology societies that dispute each other’s claims to the procedure. Second, the incentive runs the opposite way for institutional payers: insurers and national health systems reimburse 5-fluorouracil and light-activated drug therapy for sun-damaged skin but not laser resurfacing, which costs several times more per field treated, so almost no payer-funded research compares laser field therapy against the far cheaper drugs it might displace.

Mechanism of Action

Laser resurfacing deposits light energy into water, the dominant chromophore (the molecule that absorbs the light) in skin. Ablative devices — CO₂ at 10,600 nm and erbium:YAG at 2,940 nm — vaporise the epidermis (outer skin layer) and a controlled depth of dermis (the collagen-rich layer beneath). Erbium:YAG sits closer to water’s absorption peak, so it ablates cleanly with less residual heat; CO₂ leaves a coagulated rim that tightens tissue but raises pigment-change risk. Non-ablative devices (1,550 nm erbium-glass, 1,927 nm thulium) heat without vaporising, leaving the outer layer intact.

Fractional delivery splits the beam into microscopic treatment zones (MTZs, columns roughly 100 µm across and 300 µm deep) separated by untreated skin that supplies cells for rapid repair, first demonstrated by Manstein et al.

The repair cascade is the therapeutic event, not the ablation. Thermal injury denatures collagen and induces heat-shock proteins, briefly raising matrix metalloproteinases (MMPs, enzymes that dismantle old collagen) and then driving sustained type I and III collagen synthesis via transforming growth factor beta (TGF-β, the main collagen-building growth signal). Increased dermal thickness and new connective-tissue growth (fibroplasia) are visible on biopsy months later.

A competing account holds that the durable effect comes less from new collagen than from destroying senescent (aged, non-dividing) fibroblasts and restoring insulin-like growth factor 1 (IGF-1, a fibroblast growth signal), which normalises how aged skin responds to ultraviolet light. Laser resurfacing is a device, not a pharmacological compound, so half-life, receptor selectivity, tissue distribution and enzymatic metabolism do not apply.

Historical Context & Evolution

The carbon dioxide laser was built as a surgical cutting and coagulating tool, and its first dermatologic use was destroying warts, keratoses (rough scaly growths) and other benign growths. Continuous-wave output could not be confined to the epidermis and frequently scarred, so it was never a cosmetic instrument. That changed in the mid-1990s, when high-energy pulsed and rapidly scanned CO₂ systems shortened tissue dwell time enough to ablate layer by layer. Resurfacing was adopted as a replacement for dermabrasion and deep phenol peeling, and results on facial wrinkles were unlike anything topical treatment produced.

The findings themselves, not merely the reception of them, drove the reversal that followed. In a 211-procedure series, wrinkles were almost completely ablated at three and six months and much of that held at one year, but 21% developed hyperpigmentation (darkening of treated skin), 8% hypopigmentation (pigment loss), 6% infection, 6% scleral show (visible white below the iris) and 1% scarring. Two to three weeks of open wound care and months of redness made the trade unattractive, and demand fell.

Fractional photothermolysis in 2004 reopened the field by injuring only a fraction of the surface. Opinion has not settled there. Some practitioners argue fractional devices systematically under-treat, and an international panel convened in 2025 specifically on fully ablative complications — a sign the older technique persists rather than having been superseded. Separately, evidence that resurfacing clears precancerous lesions has begun reframing it as potentially preventive rather than purely cosmetic.

Expected Benefits

High 🟩 🟩 🟩

Reduction of Facial Wrinkles and Photoaging Severity

The best-evidenced benefit is measurable improvement in rhytides (wrinkles) and overall sun-damaged (photoaged) appearance, driven by dermal collagen remodelling. Split-face randomized trials pooled in a systematic review favour CO₂ over erbium:YAG for wrinkles, while a meta-analysis of randomized trials found no significant device advantage on small samples — so device choice matters less than the literature’s marketing suggests. Improvement is partly durable: the gain from a single fractional treatment was still present two years later, but it is not permanent.

Magnitude: Pulsed CO₂ near-completely ablated rhytides at three to six months with partial relapse by one year in a 211-procedure series; non-ablative fractional treatment improved wrinkle score 18% at three months; fractional CO₂ gains were stable at 24 months.

Improvement of Atrophic Acne Scarring

Fractional resurfacing remodels the depressed, tethered scars left by inflammatory acne, the same collagen-deposition mechanism applied to a structural defect rather than to diffuse ageing. Two independent meta-analyses of head-to-head trials agree that CO₂ and erbium devices both work, with CO₂ modestly ahead on physician-rated response. Evidence quality is limited by small trials and short follow-up, and most participants had Fitzpatrick phototypes I–IV (a six-level scale of how skin reacts to sun).

Magnitude: Across five comparative studies, erbium devices achieved greater-than-50% clinical response less often than fractional CO₂ (risk ratio 0.69, 95% confidence interval 0.49–0.97), at the cost of 3.67 more days of downtime for CO₂.

Clearance of Actinic Keratoses

Actinic keratoses (rough precancerous patches caused by sun damage) are removed along with the ablated epidermis, and the healed field is repopulated from untreated adnexal (hair follicle and gland) cells. This is a clinical endpoint counted by blinded assessors in more than one controlled study, including on the forearms rather than only the face. Fully ablative resurfacing outperforms fractional here, and one review rates it comparable to topical 5-fluorouracil but below photodynamic therapy (a light-activated drug treatment).

Magnitude: A single fractionated treatment cut absolute lesion count 62% at six months versus the untreated contralateral arm in 30 participants aged 60 and over; four monthly 1927 nm sessions significantly reduced counts in 23 patients.

Medium 🟩 🟩

Reduced Incidence of Keratinocyte Carcinoma in Photodamaged Skin

The most consequential claim for a longevity-focused audience is that resurfacing does not merely clear existing precancers but lowers the rate at which new keratinocyte carcinomas (basal and squamous cell skin cancers) appear. The proposed mechanism is elimination of senescent dermal fibroblasts, restoring IGF-1 signalling and a normal ultraviolet-damage response in aged skin. Evidence rests on one randomized within-person trial plus supporting animal and retrospective data, so the grade is Medium rather than High.

Magnitude: In 48 participants aged 60 and over followed up to 36 months, the treated arm developed 2 keratinocyte carcinomas versus 24 on the untreated arm, with sustained reduction in actinic keratoses (Spandau et al.).

Enhanced Delivery and Efficacy of Topical Agents

The microscopic channels created by ablative fractional lasers bypass the stratum corneum (the skin’s outermost barrier layer) and let topical drugs reach the epidermis and dermis at concentrations unattainable by simple application. This converts resurfacing from a standalone treatment into a delivery platform — most established for photodynamic therapy of sun-damaged fields, and used clinically for corticosteroids into scars. Evidence-based guidelines now specify channel-depth and molecule-size matching, with antiviral but not antibiotic prophylaxis.

Magnitude: Laser-assisted photodynamic therapy achieved higher actinic keratosis clearance than photodynamic therapy alone across four randomized trials (risk ratio 1.33, 95% confidence interval 1.24–1.42) without extra pain.

Improvement of Melasma ⚠️ Conflicted

Melasma (patchy brown facial discoloration, often hormonally driven) is the one pigment condition where resurfacing can help or harm. A meta-analysis of 14 randomized trials found ablative fractional laser added to topical therapy improved severity scores, but the same analysis found laser alone no better than other lasers, and rebound darkening is well documented. A separate meta-analysis of lasers versus chemical peels favoured lasers for melasma specifically. The net reading is that laser is a conditional add-on to topical therapy, never a first-line single treatment.

Magnitude: Adding ablative fractional laser to drug therapy improved the Melasma Area and Severity Index by a mean difference of 1.54 (95% confidence interval 0.16–2.92); alone it was not superior to other lasers (mean difference 2.66, 95% confidence interval −1.32 to 6.64) (Zhao et al.).

Reduction of Solar Lentigines and Mottled Dyspigmentation

Sun-induced brown spots and uneven tone respond to devices that target the epidermal melanin layer, particularly the 1927 nm thulium wavelength. Blinded photographic assessment and instrumented imaging both show improvement across multiple prospective studies, though all are uncontrolled series. The effect is the least durable of the benefits here: pigment drifts back toward baseline within months unless photoprotection is strict and treatments are repeated.

Magnitude: After two non-ablative 1927 nm sessions, blinded assessors rated lentigines moderately to very significantly improved in 68% of 39 patients at one month and 51% at three months; instrumented imaging showed 7.5–9.9% pigment reduction.

Low 🟩

Increased Dermal Thickness and New Collagen Deposition

Paired biopsies before and after treatment show the structural basis of the clinical effect: thicker dermis, new connective tissue, and abnormal cells confined to shallower layers. These are human histological outcomes, but the studies are uncontrolled series with few biopsies, and thickness has not been validated against any clinical endpoint.

Magnitude: Dermal thickness and fibroplasia increased significantly after four 1927 nm sessions in 20 biopsied patients; the literature reports statistical significance but no effect-size figure for thickness change.

Speculative 🟨

Local Senescent-Cell Clearance as a Tissue-Level Longevity Mechanism

Framing resurfacing as a physical senolytic means clearing aged fibroblasts to reset a tissue’s damage response. The basis is xenograft and mechanistic work only, with no human trial of ageing endpoints.

Immune-Mediated Surveillance of the Treated Field

Ablative fractional injury recruits immune cells and alters cutaneous immune signalling, which could plausibly extend surveillance beyond the ablated columns. Only laboratory and animal data exist.

Benefit-Modifying Factors

  • Fitzpatrick skin phototype and pigment genetics: Variants in MC1R (a gene setting melanin type and amount) and other pigmentation genes fix baseline melanin. Phototypes IV–VI require reduced energy and density, which directly caps achievable ablation depth and benefit.

  • Baseline photodamage severity: Absolute gain scales with what there is to correct. Higher baseline sun-damage grade, higher lesion counts and deeper rhytides produce larger measured improvements; lightly damaged skin has less headroom and often disappoints relative to expectation.

  • Baseline biomarker levels: Glycated haemoglobin, ferritin, zinc, albumin and 25-hydroxyvitamin D govern re-epithelialisation (regrowth of the skin surface) speed. Poor glucose control or nutrient deficits slow closure, prolong inflammation and blunt the collagen response that produces the benefit.

  • Sex-based differences: Men carry a thicker dermis and a denser reservoir of hair follicles and glands, which speeds surface regrowth but demands more aggressive settings for equivalent effect. Women present more often with perioral rhytides, where movement erodes results fastest.

  • Pre-existing health conditions: Smoking, diabetes, prior radiotherapy to the field, autoimmune connective-tissue disease and immunosuppression all deplete or impair the adnexal cells that repopulate ablated skin, reducing both the size and the durability of improvement.

  • Age and adnexal reserve: Older skin heals more slowly because follicle density falls, yet it also carries the largest senescent-fibroblast burden. The precancer and skin-cancer signal was demonstrated specifically in people aged 60 and over, so older age raises rather than lowers expected preventive benefit.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Post-Inflammatory Hyperpigmentation

Thermal injury stimulates melanocytes (the skin’s pigment-producing cells), producing brown discoloration of the treated field weeks after the procedure. It is the most common meaningful complication and the main reason darker phototypes are treated conservatively. It is usually transient and responds to pigment-suppressing topicals, but the months spent waiting are the practical cost. Rates depend heavily on device, pulse duration and phototype, and preventive topical regimens reduce but do not abolish it.

Magnitude: 38.4% after erbium:YAG resurfacing in phototypes III and above with mean onset 3.5 weeks and clearance within 16 weeks in 93%; 40% transient after variable-pulsed erbium:YAG; 21% after pulsed CO₂.

Prolonged Erythema, Edema and Crusting

Redness (erythema), swelling (edema) and crusting are obligate consequences of the wound, not avoidable side effects, and their duration is the main determinant of downtime. Most resolves within a week after fractional treatment, but a minority carries visible redness for more than a month, and full-field ablative resurfacing historically produced months of it. Redness beyond the expected window is also the earliest warning sign of impending scarring and prompts review rather than reassurance.

Magnitude: Erythema averaged 5.2 ± 2 days and crusting 4.1 ± 1.9 days after fractional CO₂; 15.2 days pooled across laser monotherapy arms; exceeded one month in 6% after variable-pulsed erbium:YAG.

Procedural Pain

Ablative resurfacing is painful enough that topical anaesthetic alone is often insufficient; nerve blocks, oral analgesia or sedation are standard for full-face treatment. Pain scales in randomized comparisons consistently separate the modalities, with CO₂ hurting more than erbium and lasers hurting more than chemical peels. Pain is short-lived and fully reversible, but it shapes device choice, drives demand for deeper anaesthesia and is a common reason people abandon a planned treatment series.

Magnitude: Fractional CO₂ scored 1.86 points higher than erbium devices on pain scales (95% confidence interval 1.33–2.39) in a meta-analysis; lasers carried 4.42 times the risk of procedural pain versus chemical peels.

Herpes Simplex Virus Reactivation

Thermal injury to perioral skin reactivates latent herpes simplex virus, and on a de-epithelialised field the resulting infection can spread widely and scar rather than staying localised. Reactivation occurs in people with no recalled history of prior outbreaks, which is why prophylaxis is given universally rather than by serology. Prophylaxis reduces but does not eliminate the risk, and once-daily dosing appears inadequate for ablative procedures.

Magnitude: Facial herpes complicated 10.6% of 46 fractional CO₂ treatments despite valaciclovir 500 mg once daily; 0.7% after full-face resurfacing in a 424-patient periocular series using standard prophylaxis.

Delayed Hypopigmentation

Loss of pigment appears months to years after treatment, is often permanent, and is the complication that most damaged the reputation of full-field CO₂ resurfacing in the 1990s. It arises from melanocyte destruction and from the sharp demarcation between treated and untreated skin, so it is most conspicuous at the jawline and hairline. Fractional and non-ablative devices reduce but do not remove the risk, and no reliably effective correction exists.

Magnitude: 8% after pulsed CO₂ in a 211-procedure series; 13.7% after erbium:YAG resurfacing with mean onset two months, resolving within a year in 85% and therefore persisting in the remainder.

Hypertrophic or Atrophic Scarring

Excessive depth, stacked passes, heat accumulation, infection or treatment of thin-dermis sites such as the neck, chest and eyelids can convert a controlled wound into a permanent scar, either hypertrophic (raised and thickened) or atrophic (sunken). This is the most serious non-ocular complication and is largely preventable through technique; pooled data link it to energy-setting and surgical choices rather than to device class. Absolute rates are low across large series but non-zero even in expert hands, and early treatment of developing scars materially changes the outcome.

Magnitude: Hypertrophic scarring in 5 of 1,093 patients across 34 studies; 0.51% pooled when resurfacing accompanied facelift surgery; 1% in a 211-procedure CO₂ series.

Medium 🟥 🟥

Bacterial and Atypical Mycobacterial Infection

An ablated face is an open wound under occlusive ointment, which favours bacterial overgrowth and, less often, atypical mycobacteria that present as slow-growing papules weeks later and need months of combination antibiotics. A comparative series of 133 full-face CO₂ treatments found routine antibiotic prophylaxis did not reduce infection, so surveillance and prompt culture matter more than pre-emptive antibiotics. Evidence is consistent observational data across several series rather than trial-derived.

Magnitude: Infection in 6% of a 211-procedure series; 0.74% pooled secondary superficial infection with concurrent facelift; culture-proven atypical mycobacterial infection in 2 of 424 periocular patients.

Acneiform Eruption and Milia

Occlusive post-procedure ointments plus disrupted follicular openings commonly produce an acne flare or crops of milia (small keratin cysts) in the second and third weeks. It is cosmetically unwelcome at exactly the point people expect to look better, and it is frequently mistaken for infection. It resolves with a switch to lighter emollients and, if needed, short-course topical or oral therapy, and it leaves no lasting mark.

Magnitude: Acne complicated 2.2% of fractional CO₂ treatments; acneiform events did not differ significantly between fractional CO₂ and erbium devices (odds ratio 0.73, 95% confidence interval 0.12–4.25) in a meta-analysis.

Low 🟥

Contact Dermatitis to Post-Procedure Topicals

A barrier-free wound absorbs applied products far more readily than intact skin, so antibiotic ointments and fragranced or botanical emollients provoke allergic contact dermatitis (an itchy rash from an applied substance). The redness mimics infection and feeds hyperpigmentation. Evidence is one uncontrolled retrospective series; plain petrolatum is the remedy.

Magnitude: Contact dermatitis from prescribed topical antibiotic drops or ointment in 22 of 424 patients (5.2%) after ablative CO₂ resurfacing of the lower eyelids.

Ectropion and Eyelid Malposition

Resurfacing the lower eyelid tightens skin that may be all that holds the lid in position, and in susceptible eyes this pulls the lid margin from the globe. The milder form, scleral show, is far more common than frank ectropion. Evidence is retrospective and confounded by concurrent eyelid surgery.

Magnitude: Scleral show in 6% of a 211-procedure series; pooled ectropion 0.12% with concurrent facelift.

Speculative 🟨

Occupational Exposure to Laser Plume

Vaporised tissue aerosolises cellular debris and viral nucleic acid, a theoretical transmission and respiratory hazard for operators and patients. No human outcome data exist, only laboratory detection studies and simulation work.

Risk-Modifying Factors

  • Fitzpatrick phototype and pigmentation genetics: Baseline melanin, shaped by MC1R and TYR (the melanin-making enzyme gene) variants, is the strongest single predictor of pigment complications. Phototypes IV–VI face the highest hyperpigmentation risk; phototypes I–II the highest delayed-hypopigmentation risk.

  • Baseline biomarker levels: Elevated glycated haemoglobin, low ferritin, low zinc, low albumin and low 25-hydroxyvitamin D each slow surface regrowth. Prolonged open-wound time raises infection, prolonged redness and scarring risk in direct proportion.

  • Sex-based differences: Melasma and post-inflammatory hyperpigmentation are markedly more common in women, partly through oestrogen-driven melanocyte activity. Men’s denser terminal hair carries higher folliculitis (inflamed hair follicles) risk in the beard field after ablative treatment.

  • Pre-existing health conditions: Prior herpes simplex infection, keloid history (raised overgrown scars), vitiligo or psoriasis (where injury seeds new lesions), active smoking, uncontrolled diabetes, immunosuppression and prior radiotherapy each raise infection, scarring or pigment-loss risk.

  • Age and skin reserve: Older skin has fewer follicles to repopulate ablated areas, so surface regrowth is slower and scarring risk higher at identical settings. Thin, atrophic elderly skin on the neck and chest demands markedly reduced density.

Key Interactions & Contraindications

  • Isotretinoin (prescription retinoid): Historically an absolute contraindication for 6–12 months over feared atypical scarring. A 2017 systematic review with consensus recommendations, authored by a panel that performs these procedures, found no evidence supporting delay for fractional resurfacing; caution persists for fully ablative treatment.

  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel, low-dose aspirin): Caution rather than contraindication. Increased bruising, oozing and prolonged crusting. Protocols continue medically necessary anticoagulation, schedule around elective dose changes and anticipate slower crust separation.

  • Photosensitising prescription drugs (doxycycline, hydrochlorothiazide, amiodarone, voriconazole): Caution. Amplified redness and post-inflammatory hyperpigmentation on the treated field. Where clinically permissible, they are substituted or paused before treatment, with absolute photoprotection enforced afterwards.

  • Systemic immunosuppressants and corticosteroids (prednisone, tacrolimus, mycophenolate): Caution, or absolute contraindication at high doses. Delayed surface regrowth, higher infection and scarring risk. Treatment is reserved for the lowest effective settings, with extended antimicrobial surveillance.

  • Parenteral gold therapy: Absolute contraindication. Laser irradiation of gold-laden skin precipitates chrysiasis — permanent blue-grey discoloration. No mitigation exists; gold exposure at any time excludes treatment.

  • Over-the-counter analgesics and supplements affecting clotting (ibuprofen, naproxen, aspirin, fish oil, vitamin E, ginkgo, garlic, ginger, high-dose curcumin): Caution. Increased bruising and oozing. These are stopped 7–10 days before, with paracetamol substituted.

  • Over-the-counter topical actives (retinoids, alpha-hydroxy and beta-hydroxy acids, benzoyl peroxide, physical scrubs): Caution. Compounded epidermal injury and prolonged redness. These are stopped 5–7 days before and resumed only after the surface has fully closed.

  • St John’s wort (over-the-counter herbal): Caution. Hypericin is photosensitising and raises post-procedure redness and pigment risk. It is discontinued at least two weeks before treatment and throughout the photoprotection window.

  • Supplements with additive effects on the same targets: Oral and topical vitamin C, zinc, collagen peptides, arnica and bromelain act on the same collagen-synthesis and bruise-resolution pathways the procedure engages. Additive rather than antagonistic; monitor only.

  • Other interventions (chemical peels, microneedling, radiofrequency, photodynamic therapy, dermal fillers, neuromodulators, facelift): Caution when stacked. Combining energy modalities in one session prolongs redness; pooled facelift data show higher skin-slough rates when undermined flaps receive full energy.

Populations who should avoid Laser Resurfacing:

  • Active herpes simplex outbreak, impetigo or any untreated infection in the treatment field
  • Prior parenteral gold therapy at any point in life
  • Documented keloid tendency, or hypertrophic scarring after previous resurfacing
  • Active scleroderma, dermatomyositis or other connective-tissue disease involving the skin
  • Unstable vitiligo or active psoriasis in the field, because injury seeds new lesions
  • Uncontrolled diabetes (glycated haemoglobin above 8%) or any non-healing skin ulceration
  • Prior radiotherapy to the treatment field, which destroys the adnexal cells needed for repair
  • Pregnancy or breastfeeding, because of anaesthetic and prophylactic drug exposure
  • Fully ablative treatment in Fitzpatrick phototypes V–VI, where permanent pigment loss risk is prohibitive
  • Lower-eyelid treatment with pre-existing lid laxity, prior eyelid surgery or a positive snap-back test
  • Active smoking within four weeks before and after treatment
  • Sunburn or recent intensive ultraviolet exposure in the field within four weeks

Risk Mitigation Strategies

  • Universal antiviral prophylaxis: Prevents herpes simplex reactivation and the scarring it can cause. Valaciclovir 500 mg twice daily from one day before until the surface has closed; once-daily dosing proved inadequate in fractional CO₂ practice.

  • Phototype-matched settings with a test spot: Reduces post-inflammatory hyperpigmentation. Protocols lower fluence (energy delivered per unit area) and cut density to 5–15% for phototypes IV–VI, with a concealed test area treated 4–6 weeks ahead to gauge pigment response.

  • Pre- and post-procedure pigment suppression: Blunts melanocyte activation by inhibiting tyrosinase (the enzyme that makes melanin). Hydroquinone 4% for 2–4 weeks before and after healing, with daily SPF 50 (sun protection factor) sunscreen and strict sun avoidance for three months.

  • Conservative density and pass discipline: Prevents heat stacking and scarring. Passes are not overlapped on the same zone, density stays below 20% on the neck, chest and eyelids, and cooling intervals separate passes.

  • Plain petrolatum-only aftercare: Avoids allergic contact dermatitis, which affected 5.2% of one eyelid series through prescribed antibiotic topicals. Aftercare is white petrolatum with dilute acetic acid soaks, without fragrances, botanicals or topical antibiotics.

  • Surveillance instead of routine antibiotic prophylaxis: Comparative series found prophylaxis did not lower infection rates. Review falls at days 3–7, any pustule or persistent papule is cultured, and atypical mycobacterial infection is treated on culture rather than empirically.

  • Corneal eye shields for periocular work: Prevents irreversible corneal and retinal injury. Internal metal shields with lubricant are mandatory whenever the beam enters the orbital rim region; external goggles are insufficient for eyelid treatment.

  • Early intervention for developing scars: Persistent focal redness or firmness beyond four weeks is the warning sign. Intralesional triamcinolone 2.5–10 mg/mL plus pulsed-dye laser at that stage usually prevents a permanent thickened scar.

  • Preoperative metabolic and behavioural optimisation: Shortens open-wound time and lowers infection risk. Glycated haemoglobin below 7%, complete smoking cessation four weeks before and after, and correction of low ferritin, zinc or vitamin D.

  • Energy reduction over undermined surgical flaps: Prevents skin slough when resurfacing accompanies facelift surgery, where pooled data link full-energy treatment of dissected areas to significantly higher slough rates. Fluence and density are reduced over undermined tissue.

Therapeutic Protocol

  • Fully ablative resurfacing (the aggressive approach): A single full-field CO₂ or erbium:YAG session at high fluence, 7–14 days of open wound care, months of redness. Championed by facial-plastic surgeons including Kevin Duplechain and Jason Pozner.

  • Ablative fractional resurfacing (the mainstream compromise): Fractional CO₂ or erbium:YAG, typically 1–3 sessions spaced 4–8 weeks apart, 5–7 days of visible healing. Codified by an expert consensus panel whose members earn revenue from performing the procedure.

  • Non-ablative fractional resurfacing (the low-downtime approach): 1,550 nm erbium-glass or 1,927 nm thulium, 3–6 sessions at 2–4 week intervals, 2–3 days of redness. Popularised through the Fraxel platform by Roy Geronemus at New York’s Laser & Skin Surgery Center.

  • Selecting between approaches: No approach is the default. Randomized-trial meta-analysis found no significant efficacy separation between tissue-removing and tissue-heating devices, so downtime tolerance, phototype and scarring risk drive the choice more than expected efficacy.

  • Representative settings: Fractional CO₂ at 10–30 mJ per microbeam and 5–20% coverage for facial sun damage; 1,927 nm thulium at 10–15 mJ with 15–40% coverage and 4–6 passes for uneven pigment; reduced density off-face.

  • Anaesthesia: Topical anaesthetic cream is standard, used by 95% of consensus panellists, with regional nerve blocks (81%) and oral analgesia (62%) added for ablative treatment. Full-field ablative work often requires sedation.

  • Best time of day: No chronobiological data exist. Morning scheduling is conventional so that the first hours of oozing and swelling occur under supervision, and evening treatment is avoided because overnight swelling peaks unobserved.

  • Seasonal timing: Scheduling falls in autumn or winter. Ultraviolet exposure in the weeks after treatment is the strongest modifiable driver of post-inflammatory hyperpigmentation, and pigment gains reverse fastest when treatment is followed by summer.

  • Not a pharmacological agent: Half-life, single versus divided dosing, and metabolic clearance do not apply to a device. The analogous dose variables are fluence, coverage density, pulse duration and number of passes.

  • Pre-conditioning: Topical tretinoin for 2–4 weeks before treatment thins the stratum corneum and speeds surface regrowth; hydroquinone is added for phototypes III and above. Both are stopped 5–7 days before the session.

  • Genetic considerations: No pharmacogenetic test guides settings. Pigmentation-gene variants expressed as the MC1R red-hair phenotype signal both high delayed-hypopigmentation risk and low melanin protection, while a family history of keloids argues against ablative depth.

  • Sex-based considerations: Men’s thicker dermis and denser follicles tolerate and often require higher fluence for equivalent effect; women more often present with perioral rhytides, which need deeper treatment and relapse fastest with continued muscular movement.

  • Age-related considerations: In people over 60, follicle and gland density is low, so density is reduced and healing time extended. Older skin is nonetheless the population in which the precancer and skin-cancer benefit has been demonstrated.

  • Baseline biomarkers influencing response: Glycated haemoglobin, ferritin, zinc, albumin and 25-hydroxyvitamin D are checked and corrected before treatment because each governs surface-regrowth speed, which in turn determines both outcome quality and complication risk.

  • Pre-existing conditions influencing response: Active acne, rosacea and melasma are stabilised first. Untreated melasma may rebound, active acne seeds post-procedure pustules, and rosacea predicts prolonged redness after any energy-based treatment.

  • Post-procedure care: Dilute acetic acid soaks four to six times daily under plain petrolatum until the surface closes, typically 5–7 days for fractional and up to two weeks for fully ablative treatment. Sunscreen resumes once the surface is closed.

Discontinuation & Cycling

  • Episodic, not lifelong: Laser resurfacing is a discrete procedure rather than a continuous therapy. There is nothing to discontinue; the question is whether and when to repeat, and results persist for years without further treatment.

  • No withdrawal effects: Stopping produces no rebound, physiological dependence or deterioration below baseline. Skin simply resumes its previous ageing trajectory; the 21% hyperpigmentation and 8% hypopigmentation risks are treatment effects, not withdrawal effects.

  • No tapering protocol applies: Because no agent is administered continuously, there is nothing to taper. Where a planned multi-session course is abandoned early, gains already achieved are retained rather than lost.

  • Maintenance intervals rather than cycling: Efficacy is not maintained by cycling. Non-ablative fractional gains typically warrant repeat treatment every 12–24 months; fractional CO₂ results from a single session held stable at 24 months.

  • Photoprotection determines durability: Continued ultraviolet exposure erodes results faster than any schedule of repeat sessions. Pigment benefits in particular drift back toward baseline within three months without strict daily photoprotection.

Sourcing and Quality

  • Practitioner selection over device selection: Complications track operator judgement more than device class. The relevant marker is a board-certified dermatologist, plastic surgeon, facial-plastic surgeon or oculoplastic surgeon who personally operates the device rather than delegating it.

  • Device regulatory clearance: Relevant clearance is US Food and Drug Administration (FDA) 510(k) — the pathway for devices equivalent to one already marketed — or regional equivalent, granted for skin resurfacing rather than an adjacent indication such as hair removal.

  • Established device platforms: Long-marketed systems from manufacturers such as Lumenis, Solta (Fraxel), Sciton and Candela carry published parameter sets and a service network; obscure or unbranded units leave no way to reproduce settings or verify output.

  • Grey-market and counterfeit hardware: Uncleared imports and refurbished units with non-original parts deliver unverified fluence and unstable pulse durations. The serial number, the manufacturer’s service record and the date of last calibration are the documents that settle provenance.

  • Delegation and supervision rules: In many jurisdictions non-physicians may operate lasers under variable supervision. The decisive facts are who holds the handpiece, what their training is, and whether a physician is physically present during treatment.

  • Plume evacuation and eye protection: A functioning smoke evacuator with an ultra-low-penetration-air filter and wavelength-specific eyewear for everyone in the room are markers of a properly run laser suite and reduce occupational plume exposure.

  • Post-procedure product quality: The skin is barrier-free for days, so pharmaceutical-grade white petrolatum outperforms fragranced or botanical-containing balms; contact dermatitis from post-procedure topicals affected 5.2% of one large eyelid series.

Practical Considerations

  • Time to effect: Immediate improvement is wound swelling, not result. Pigment gains show at one month, wrinkle and texture gains at three months as collagen remodels, and the final result is judged at six months.

  • Pitfall — treating in the wrong season: Ultraviolet exposure in the weeks after treatment is the leading avoidable cause of post-inflammatory hyperpigmentation. Booking in late spring so results “look good for summer” inverts the correct sequence.

  • Pitfall — under-treating to avoid downtime: Repeated low-density sessions marketed as lunchtime procedures rarely reach the dermal depth that produces durable remodelling, and often cost more in aggregate than one properly dosed treatment.

  • Pitfall — treating the face and ignoring the neck: A rejuvenated face above untreated neck and chest skin reads as obviously treated. Off-face skin needs markedly lower density, so it requires planning rather than omission.

  • Pitfall — stopping photoprotection once healed: Gains erode within months without daily broad-spectrum sunscreen. This is the single behaviour that separates people who keep results from those who repeat the procedure early.

  • Regulatory status: Resurfacing devices are cleared as medical devices, not approved as drugs, so cleared indications are broad and comparative efficacy is not required for market entry. Skin-cancer prevention is an off-label use.

  • Cost and accessibility: Cosmetic resurfacing is paid out of pocket almost everywhere, typically USD 1,000–2,500 per non-ablative fractional session and USD 2,500–6,000 for full-face fully ablative treatment, placing a properly dosed course beyond many budgets.

Interaction with Foundational Habits

  • Sleep: Indirect and bidirectional. Sleep restriction measurably slows skin-barrier recovery, so poor sleep in the first post-procedure week prolongs the open-wound phase. In the other direction, facial swelling and the need to sleep on the back with the head elevated for several nights disrupt sleep, so treatment is usually scheduled before a low-demand week.

  • Nutrition: Direct and potentiating. Collagen synthesis is rate-limited by protein, ascorbate, zinc and iron, so intake of 1.2–2.0 g protein per kilogram body weight daily with adequate vitamin C supports repair. Alcohol is avoided for a week because it worsens swelling, as are high-dose fish oil and vitamin E for bruising reasons.

  • Exercise: Blunting and temporarily restricted. Sweat on an unhealed field raises infection risk and stings, and exercise-driven vessel dilation prolongs redness. Strenuous training, sauna, hot yoga and swimming pools are avoided for 5–7 days after fractional treatment and up to two weeks after fully ablative treatment; walking is unrestricted.

  • Stress management: Indirect and blunting. Sustained cortisol elevation delays wound closure and suppresses local immune response, which on a resurfaced face means longer redness and higher infection risk. There is no laser-specific trial, so the mechanism is extrapolated from general wound-healing research rather than demonstrated for this procedure.

Monitoring Protocol & Defining Success

Before treatment, a clinician documents Fitzpatrick phototype, Glogau photoaging grade (a four-level scale of sun-damage severity), actinic keratosis count and standardised photography under fixed lighting, and performs a snap-back test (a bedside check of lower-eyelid tone) if that lid is to be treated. A baseline blood panel identifies the metabolic and nutritional constraints that govern surface regrowth, since open-wound time drives every major complication. Afterwards the cadence follows wound biology rather than laboratory values: a wound check at days 3–7, closure confirmation at two weeks, pigment assessment at 4–6 weeks when hyperpigmentation typically emerges, and outcome photography at three and six months once collagen remodelling has run its course. Metabolic markers are rechecked only before any subsequent session, and actinic keratosis counts every 6–12 months where prevention is the aim.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Glycated haemoglobin (HbA1c) 4.8–5.4% High glucose slows surface regrowth and raises infection risk HbA1c reflects average blood sugar over about three months. Conventional “normal” extends to 5.6%; fasting not required; pair with fasting insulin
25-hydroxyvitamin D 40–60 ng/mL (100–150 nmol/L) Supports keratinocyte proliferation and barrier restoration Conventional sufficiency starts at 30 ng/mL; draw any time of day; recheck 8–12 weeks after a dose change
High-sensitivity C-reactive protein (hs-CRP) Below 0.5 mg/L Baseline inflammation predicts prolonged post-procedure redness hs-CRP is a general marker of body-wide inflammation. Conventional low-risk threshold is 1.0 mg/L; defer during acute illness; pair with ferritin
Serum ferritin 50–125 ng/mL (women), 50–150 ng/mL (men) Iron is a cofactor for collagen cross-linking; low stores slow closure Rises with inflammation, so interpret alongside hs-CRP; fasting preferred; pair with transferrin saturation
Serum zinc 90–120 µg/dL Zinc deficiency delays wound contraction and cell migration Draw fasting in the morning; withhold zinc supplements 24 hours before; pair with serum copper
Serum albumin 4.2–5.0 g/dL Indicates protein availability for new collagen deposition Conventional normal starts at 3.5 g/dL; pair with total protein; falls in inflammation independent of nutrition
Haemoglobin 13.5–15.0 g/dL (women), 14.0–16.0 g/dL (men) Low values reduce oxygen delivery to healing tissue Part of a complete blood count; fasting not required; repeat only if the baseline is abnormal
Herpes simplex virus type 1 antibody (HSV-1 IgG) No established target; the result is simply positive or negative. Where it is negative, track personal outbreak history instead Identifies who carries the latent virus that thermal injury reactivates HSV-1 IgG is an antibody showing past exposure. People testing negative still receive antiviral prophylaxis, so a negative result does not change the protocol

Qualitative markers worth tracking alongside the laboratory panel and photography:

  • Day on which crusting separates completely and the surface is closed
  • Duration of visible redness, and whether it is fading or static at four weeks
  • Any focal area that stays red or firm beyond four weeks, the earliest scarring signal
  • Subjective skin texture and make-up application at three and six months
  • Recurrence of herpes simplex, acne or milia in the treated field
  • Self-rated satisfaction against the baseline photographs rather than against memory

Emerging Research

  • Long-term skin-cancer prophylaxis trial: NCT03906253 randomises one forearm of 72 participants aged 60 and over to fractionated laser resurfacing, counting actinic keratoses and non-melanoma skin cancers on both arms for five years. Primary completion is estimated for December 2028.

  • Mechanism of laser-induced rejuvenation: NCT06489301 uses single-cell sequencing of abdominoplasty specimens in 12 participants to test whether the fibroblasts appearing after resurfacing derive from blood monocytes — the cellular basis of the senescence-clearance hypothesis.

  • Multimodal laser prevention trial: NCT07789002 is a randomised split-face study in 35 patients combining 1,927 nm thulium, 1,550 nm erbium-glass and intense pulsed light against an untreated side, with gene-expression readouts and 14-month follow-up for preventive effect.

  • Next-generation wavelengths and coring: NCT07254884 evaluates a 2,910 nm fibre laser with tissue coring in 40 participants with rhytides and laxity, testing whether full-thickness tissue removal delivers ablative results without full-field ablative downtime.

  • Laser-assisted drug delivery: Evidence-based guidelines now specify how to match channel depth to molecule size, opening resurfacing as a delivery platform. Whether this improves outcomes in rejuvenation rather than cancer care remains the open question.

  • Evidence that could weaken the case: Karanasios et al., 2026 found lasers no better than far cheaper chemical peels for sun damage, acne or acne scarring, and Seirafianpour et al., 2022 found no ablative advantage — both argue current pricing outruns demonstrated benefit.

  • Contested durability of the pigment benefit: Vingan et al., 2023 showed instrumented pigment gains reverting toward baseline by three months, suggesting published one-month endpoints systematically overstate what non-ablative resurfacing achieves for uneven pigment.

Conclusion

Laser resurfacing uses controlled light injury to make the skin rebuild itself. The strongest evidence supports smoother, less wrinkled skin, real improvement in depressed acne scars, and clearance of rough sun-damaged patches; fading of brown spots rests on weaker ground and reverses soonest. Gains hold for a year or two rather than permanently. A smaller but striking finding is that treating sun-damaged skin in older people lowered the number of new skin cancers on the treated limb, which matters more to someone focused on long-term health than any change in appearance. That result comes from a single randomised study and stands alone so far.

The costs are real and mostly about pigment. Brown discoloration follows in a large minority, loss of pigment can be permanent, and pain, redness, herpes flare-ups and occasional scarring are all documented. Darker skin carries more pigment risk, and treatment there is given at gentler settings.

The evidence base itself is uneven. Much of it comes from device makers, from panels of surgeons who earn their income performing the procedure, and from small studies with short follow-up. Insurers pay for cheaper drug treatments of sun damage but not for lasers, which shapes what gets studied and what gets compared. Head-to-head comparisons with chemical peels found no clear winner, so neither the enthusiastic nor the dismissive reading is settled.

Top - Benefits - Risks - Protocol